Compare Sanofi SA (SNY) vs Teradata Corporation Common Stock (TDC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs Teradata Corporation Common Stock — how do they compare? Sanofi SA trades at $40.51 (market cap $94.58B), while Teradata Corporation Common Stock trades at $29.6 (market cap $2.83B). The key difference: Sanofi SA is far larger — about 33.4× Teradata Corporation Common Stock's market cap, and Sanofi SA pays a 6.18% dividend while Teradata Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Sanofi SA for 94 Days and Teradata Corporation Common Stock for 0 Days on average.
| SNY | TDC | |
|---|---|---|
Market Cap | $94.58B | $2.83B |
Volume | 3,988,460 | 1,343,944 |
Sector | Health | Technology |
52-Week High | $52.34 | $37.88 |
52-Week Low | $39.12 | $20.71 |
Typical Hold Time | 94 Days | 0 Days |
Enterprise Value | $113.80B | $2.52B |
Dividend Yield | 6.18% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SNY trades at $39.77, up 0.08% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21 versus $1.10 expected, and announced a significant expansion of its immunology alliance with Regeneron, valued up to $8 billion. Revenue for 2025 was $46.72 billion, with net income of $7.81 billion, reflecting a profit margin of 16.72%.
The outlook is mixed; recent collaborations and earnings beats provide growth catalysts, but a projected decline in 2026 net income to $4.0 billion and bearish technical indicators suggest near-term headwinds. Risks include execution of new partnerships and competitive pressures in the pharmaceutical sector.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About Teradata Corporation Common Stock
Teradata Corporation develops a hybrid cloud analytics and data platform, including its Teradata Vantage and VantageCloud products, that helps enterprises manage and analyze data across cloud, on-premises, and hybrid environments. It serves industries including retail, financial services, healthcare, and manufacturing.
Read more on TDC →
